{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T18:30:28Z","timestamp":1789237828110,"version":"build-2803163510"},"reference-count":29,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T00:00:00Z","timestamp":1746316800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007687","name":"Swedish Society of Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007687","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009336","name":"Bengt Ihre Research Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001725","name":"Kungliga Vetenskapsakademien","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejso.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Surgical Oncology"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.ejso.2025.110123","type":"journal-article","created":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T10:44:45Z","timestamp":1746355485000},"page":"110123","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["External validation of plasma CSF1 as a preoperative prognostic marker in patients with resectable intrahepatic cholangiocarcinoma"],"prefix":"10.1016","volume":"51","author":[{"given":"Antonio","family":"Akiki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-5117-9286","authenticated-orcid":false,"given":"Hanna","family":"Jacobsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0081-7347","authenticated-orcid":false,"given":"Ghada","family":"Nouairia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Cornillet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niklas K.","family":"Bj\u00f6rkstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0259-8328","authenticated-orcid":false,"given":"Ernesto","family":"Sparrelid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8795-5250","authenticated-orcid":false,"given":"Helena","family":"Taflin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1833-854X","authenticated-orcid":false,"given":"Hannes","family":"Jansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.ejso.2025.110123_bib1","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1001\/jamasurg.2013.5137","article-title":"Treatment and prognosis for patients with intrahepatic cholangiocarcinoma: systematic review and meta-analysis","volume":"149","author":"Mavros","year":"2014","journal-title":"JAMA Surg"},{"issue":"2","key":"10.1016\/j.ejso.2025.110123_bib2","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.jhep.2019.11.020","article-title":"Liver resection and transplantation for intrahepatic cholangiocarcinoma","volume":"72","author":"Mazzaferro","year":"2020","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.ejso.2025.110123_bib3","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/nrclinonc.2017.157","article-title":"Cholangiocarcinoma \u2014 evolving concepts and therapeutic strategies","volume":"15","author":"Ilyas","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"10.1016\/j.ejso.2025.110123_bib4","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jhep.2023.03.010","article-title":"EASL-ILCA Clinical Practice Guidelines on the management of intrahepatic cholangiocarcinoma","volume":"79","author":"Alvaro","year":"2023","journal-title":"J Hepatol"},{"issue":"6917","key":"10.1016\/j.ejso.2025.110123_bib5","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/nature01322","article-title":"Inflammation and cancer","volume":"420","author":"Coussens","year":"2002","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.ejso.2025.110123_bib6","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s12253-015-9913-z","article-title":"The role of the mediators of inflammation in cancer development","volume":"21","author":"Fernandes","year":"2015","journal-title":"Pathol Oncol Res"},{"issue":"9","key":"10.1016\/j.ejso.2025.110123_bib7","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","article-title":"Cholangiocarcinoma 2020: the next horizon in mechanisms and management","volume":"17","author":"Banales","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.ejso.2025.110123_bib8","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.ejso.2019.12.008","article-title":"Prognostic value of preoperative inflammatory markers in resectable biliary tract cancer \u2013 validation and comparison of the Glasgow Prognostic Score and Modified Glasgow Prognostic Score in a Western cohort","volume":"46","author":"Jansson","year":"2020","journal-title":"Eur J Surg Oncol"},{"issue":"22","key":"10.1016\/j.ejso.2025.110123_bib9","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000033656","article-title":"Preoperative C-reactive protein-to-albumin ratio as a prognostic factor in biliary tract cancer: a systematic review and meta-analysis","volume":"102","author":"Utsumi","year":"2023","journal-title":"Medicine (Baltim)"},{"key":"10.1016\/j.ejso.2025.110123_bib10","first-page":"1","article-title":"Prognostic and clinicopathological significance of C-reactive protein to albumin ratio in patients with bile duct cancer: a meta-analysis","volume":"3","author":"Dai","year":"2022","journal-title":"Nutr Cancer"},{"key":"10.1016\/j.ejso.2025.110123_bib11","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1169537","article-title":"Preoperative immunological plasma markers TRAIL, CSF1 and TIE2 predict survival after resection for biliary tract cancer","volume":"13","author":"Jansson","year":"2023","journal-title":"Front Oncol"},{"issue":"9","key":"10.1016\/j.ejso.2025.110123_bib29","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1136\/heartjnl-2011-301247","article-title":"Risk prediction models: II. External validation, model updating, and impact assessment","volume":"98","author":"Moons","year":"2012","journal-title":"Heart"},{"issue":"16","key":"10.1016\/j.ejso.2025.110123_bib12","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1093\/jnci\/dji237","article-title":"Reporting recommendations for tumor marker prognostic studies (REMARK)","volume":"97","author":"McShane","year":"2005","journal-title":"JNCI J Natl Cancer Inst"},{"key":"10.1016\/j.ejso.2025.110123_bib13","unstructured":"Kohn MA, Senyak J. Sample Size Calculators [Internet]. UCSF Clin. Transl. Sci. Inst. [last accessed 2024 May 11]. Available from: https:\/\/sample-size.net\/sample-size-survival-analysis\/."},{"key":"10.1016\/j.ejso.2025.110123_bib14","unstructured":"Methodological consideration for using progression-free survival (PFS) or disease-free survival (DFS) in confirmatory trials. European Med. Agency. [last accessed 2024 May 16]; Available from: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/appendix-1-guideline-evaluation-anticancer-medicinal-products-man-methodological-consideration-using-progression-free-survival-or-disease-free-survival-confirmatory-trials_en.pdf."},{"key":"10.1016\/j.ejso.2025.110123_bib15","series-title":"TNM classification of malignant tumours","first-page":"309","author":"Sobin","year":"2010"},{"issue":"15","key":"10.1016\/j.ejso.2025.110123_bib16","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkr424","article-title":"Homogeneous antibody-based proximity extension assays provide sensitive and specific detection of low-abundant proteins in human blood","volume":"39","author":"Lundberg","year":"2011","journal-title":"Nucleic Acids Res"},{"issue":"4","key":"10.1016\/j.ejso.2025.110123_bib17","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0095192","article-title":"Homogenous 96-plex PEA immunoassay exhibiting high sensitivity, specificity, and excellent scalability. Hoheisel JD","volume":"9","author":"Assarsson","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.ejso.2025.110123_bib18","series-title":"Regression modeling strategies: with applications to linear models, logistic and ordinal regression, and survival analysis","author":"Harrell","year":"2015"},{"issue":"8","key":"10.1016\/j.ejso.2025.110123_bib19","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1007\/s00384-006-0259-6","article-title":"Evaluation of an inflammation-based prognostic score (GPS) in patients undergoing resection for colon and rectal cancer","volume":"22","author":"McMillan","year":"2007","journal-title":"Int J Colorectal Dis"},{"issue":"2","key":"10.1016\/j.ejso.2025.110123_bib20","first-page":"105","article-title":"The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: an evidence based appraisal","volume":"3","author":"Ballehaninna","year":"2012","journal-title":"J Gastrointest Oncol"},{"key":"10.1016\/j.ejso.2025.110123_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103375","article-title":"Tumor-associated macrophages in cholangiocarcinoma: complex interplay and potential therapeutic target","volume":"67","author":"Zhou","year":"2021","journal-title":"EBioMedicine"},{"issue":"10","key":"10.1016\/j.ejso.2025.110123_bib22","doi-asserted-by":"crossref","first-page":"5380","DOI":"10.1172\/JCI137110","article-title":"Targeting tumor-associated macrophages and granulocytic myeloid-derived suppressor cells augments PD-1 blockade in cholangiocarcinoma","volume":"130","author":"Loeuillard","year":"2020","journal-title":"J Clin Investig"},{"issue":"1","key":"10.1016\/j.ejso.2025.110123_bib23","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1186\/s12967-023-04804-1","article-title":"ALOX5 acts as a key role in regulating the immune microenvironment in intrahepatic cholangiocarcinoma, recruiting tumor-associated macrophages through PI3K pathway","volume":"21","author":"Chen","year":"2023","journal-title":"J Transl Med"},{"issue":"10","key":"10.1016\/j.ejso.2025.110123_bib24","doi-asserted-by":"crossref","first-page":"3517","DOI":"10.1158\/0008-5472.CAN-03-2770","article-title":"Mcl-1 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in human cholangiocarcinoma cells","volume":"64","author":"Taniai","year":"2004","journal-title":"Cancer Res"},{"issue":"1A","key":"10.1016\/j.ejso.2025.110123_bib25","first-page":"259","article-title":"Triptolide sensitizes resistant cholangiocarcinoma cells to TRAIL-induced apoptosis","volume":"26","author":"Panichakul","year":"2006","journal-title":"Anticancer Res"},{"issue":"5","key":"10.1016\/j.ejso.2025.110123_bib26","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.jcmgh.2024.01.006","article-title":"Noncanonical TRAIL signaling promotes myeloid-derived suppressor cell abundance and tumor growth in cholangiocarcinoma","volume":"17","author":"Loeuillard","year":"2024","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"10.1016\/j.ejso.2025.110123_bib27","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.2147\/OTT.S93629","article-title":"Intrahepatic cholangiocarcinoma: current perspectives","volume":"10","author":"Buettner","year":"2017","journal-title":"OncoTargets Ther"},{"key":"10.1016\/j.ejso.2025.110123_bib28","doi-asserted-by":"crossref","first-page":"227","DOI":"10.2147\/IJGM.S133292","article-title":"Opisthorchiasis and cholangiocarcinoma in Southeast Asia: an unresolved problem","volume":"10","author":"Hughes","year":"2017","journal-title":"Int J Gen Med"}],"updated-by":[{"DOI":"10.1016\/j.ejso.2025.111189","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000}}],"container-title":["European Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798325005517?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798325005517?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T02:39:08Z","timestamp":1765334348000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0748798325005517"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":29,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S0748798325005517"],"URL":"https:\/\/doi.org\/10.1016\/j.ejso.2025.110123","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.11.27.24318028","asserted-by":"object"}]},"ISSN":["0748-7983"],"issn-type":[{"value":"0748-7983","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"External validation of plasma CSF1 as a preoperative prognostic marker in patients with resectable intrahepatic cholangiocarcinoma","name":"articletitle","label":"Article Title"},{"value":"European Journal of Surgical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejso.2025.110123","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"110123"}}